Lexaria Bioscience (NASDAQ: LEXX) — Perfil da empresa, notícias e dados financeiros
Lexaria Bioscience develops oncolytic viral therapies to enhance drug delivery for cancer treatment, focusing on improved efficacy.
Lexaria Bioscience
Lexaria Bioscience (NASDAQ:LEXX) is a biotechnology firm deeply involved in the development of drug delivery platforms. These innovative platforms are designed to enhance the bioavailability of a broad range of active pharmaceutical ingredients (APIs), thereby improving the efficacy of products in areas such as heart disease, hypertension, and certain neurological conditions. One of their flagship projects, DehydraTECH™, aims to significantly improve the way drugs are delivered into the body, making treatments not only more effective but also potentially faster acting and with fewer side effects. Lexaria's objectives focus on leveraging its patented technology to form partnerships within the pharmaceutical, nutraceutical, and other health-related industries, aiming to create products that offer superior performance and consumer experience.
Resumo
Operações
Produtos e/ou serviços de Lexaria Bioscience
- DehydraTECH technology enhances the performance of beneficial compounds in ingestible products, improving taste, smell, and bioavailability.
- Hypertension program focuses on developing and evaluating DehydraTECH-enabled antihypertensive drugs.
- Oral nicotine product development aims to offer safer, non-combusted forms of nicotine delivery using DehydraTECH, potentially reducing harm compared to traditional tobacco products.
- Cannabidiol (CBD) product formulations leverage DehydraTECH to improve the efficiency and experiences of CBD ingestion for therapeutic use.
- Antiviral drugs program uses DehydraTECH to enhance the delivery and effectiveness of antiviral drug treatments.
- Central Nervous System (CNS) program explores DehydraTECH's potential in improving the delivery of CNS-targeting drugs, including those for pain and epilepsy.
equipe executiva do Lexaria Bioscience
- Richard C. ChristopherCEO & Director
- John M. DochertyChairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director
- Michael ShankmanChief Financial Officer
- Kristin HamiltonDirector of Operations
- Vanessa CarleHead of Legal
- C. Michael GibsonChief Medical Advisor & Member of Scientific Advisory Board
Comunicados recentes
O que a Lexaria Bioscience (LEXX) comunicou ao mercado, do mais recente para o mais antigo.
- LULD halt | LEXXFato relevante
Principais indicadores financeiros
Resultados divulgados pela Lexaria Bioscience , em USD.
- Cap. de mercado
- 6,8 mi
- Receita (TTM)
- 194 mil
- P/L
- —
- LPA (diluído, TTM)
- -5.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 705,9 mil | -11,9 mi | -11,9 mi | |
| 464,3 mil | -5,8 mi | -5,8 mi | |
| 226,2 mil | -6,5 mi | -6,7 mi | |
| 255,4 mil | -6,6 mi | -7,3 mi |